Flu vaccines managed to reduce 27 and 50 percent of the disease in patients with influenza A and B, respectively, during the 2022/2023 season, according to a report published this Friday by the European Center for Control and Prevention. Prevention of Diseases (ECDC, for its acronym in English).
According to the European body’s document, the past flu season marked the return of flu virus activity to almost pre-pandemic levels in the EU/EEA countries. This season was characterized by “an earlier onset of the seasonal epidemic and an earlier peak of positivity compared to the previous four seasons.”
The percentage of positive samples peaked at 42 percent in the week of December 19-25, followed by a decline until the week of January 23-29, 2023, when it reached 22 percent positivity, before returning again. to increase to fluctuate around 28 percent positivity between January 30 and March 26, 2023.
The 10 percent positivity threshold was exceeded in the week of April 24-30, marking the end of the seasonal flu epidemic.
In general, influenza A(H3N2) viruses predominated in primary care sentinel samples, although higher circulations of A(H1N1)pdm09 viruses (from week 50/2022) and type B (from week 50/2022) were observed. starting week 2/2023).
In non-sentinel samples, A(H3N2) viruses predominated over A(H1N1)pdm09 viruses. Both type A and type B influenza viruses have been detected in hospitalized patients in ICUs and other wards, with influenza A being the dominant type. Similarly, type A influenza viruses have been dominant among patients.
Most of the genetically characterized influenza viruses fell within the recommended vaccine component clades, according to ECDC data.
2023-07-07 15:07:00
#effectiveness #flu #vaccine #season #ECDC #Galiciapress